Itraconazole in human medicine and veterinary practice
Copyright © 2024. Published by Elsevier Masson SAS..
Diagnosis and management of fungal infections are challenging in both animals and humans, especially in immunologically weakened hosts. Due to its broad spectrum and safety profile when compared to other antifungals, itraconazole (ITZ) has been widely used in the treatment and prophylaxis of fungal infections, both in human and veterinary medicine. The dose and duration of management depend on factors such as the type of fungal pathogen, the site of infection, sensitivity to ITZ, chronic stages of the disease, the health status of the hosts, pharmacological interactions with other medications and the therapeutic protocol used. In veterinary practice, ITZ doses generally vary between 3 mg/kg and 50 mg/kg, once or twice a day. In humans, doses usually vary between 100 and 400 mg/day. As human and veterinary fungal infections are increasingly associated, and ITZ is one of the main medications used, this review addresses relevant aspects related to the use of this drug in both clinics, including case reports and different clinical aspects available in the literature.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Journal de mycologie medicale - 34(2024), 2 vom: 11. März, Seite 101473 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sousa, Yamara V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fungal diseases |
|---|
| Anmerkungen: |
Date Revised 17.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.mycmed.2024.101473 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369832914 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369832914 | ||
| 003 | DE-627 | ||
| 005 | 20240318235035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mycmed.2024.101473 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1335.xml |
| 035 | |a (DE-627)NLM369832914 | ||
| 035 | |a (NLM)38493607 | ||
| 035 | |a (PII)S1156-5233(24)00014-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sousa, Yamara V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Itraconazole in human medicine and veterinary practice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier Masson SAS. | ||
| 520 | |a Diagnosis and management of fungal infections are challenging in both animals and humans, especially in immunologically weakened hosts. Due to its broad spectrum and safety profile when compared to other antifungals, itraconazole (ITZ) has been widely used in the treatment and prophylaxis of fungal infections, both in human and veterinary medicine. The dose and duration of management depend on factors such as the type of fungal pathogen, the site of infection, sensitivity to ITZ, chronic stages of the disease, the health status of the hosts, pharmacological interactions with other medications and the therapeutic protocol used. In veterinary practice, ITZ doses generally vary between 3 mg/kg and 50 mg/kg, once or twice a day. In humans, doses usually vary between 100 and 400 mg/day. As human and veterinary fungal infections are increasingly associated, and ITZ is one of the main medications used, this review addresses relevant aspects related to the use of this drug in both clinics, including case reports and different clinical aspects available in the literature | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Fungal diseases | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Itraconazole | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Veterinary | |
| 700 | 1 | |a Santiago, Marie G |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Bianca M |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Kelly M |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Camila S F |e verfasserin |4 aut | |
| 700 | 1 | |a Mendoza, Leonel |e verfasserin |4 aut | |
| 700 | 1 | |a Vilela, Raquel V R |e verfasserin |4 aut | |
| 700 | 1 | |a Goulart, Gisele A C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal de mycologie medicale |d 1997 |g 34(2024), 2 vom: 11. März, Seite 101473 |w (DE-627)NLM093691998 |x 1773-0449 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2024 |g number:2 |g day:11 |g month:03 |g pages:101473 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mycmed.2024.101473 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2024 |e 2 |b 11 |c 03 |h 101473 | ||